Search research articles
Contact Us
Filters
Showing results (161-170 of 176) with videos related to
Page
of 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2026
Gemcitabine plus nivolumab with carboplatin or oxaliplatin in cisplatin-ineligible patients with metastatic urothelial carcinoma: a randomized phase II trial
Ziao Li, Sudeh Izadmehr, Jeannie Hoffman-Censits, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 6, 2026
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
Matthew D Galsky, Sudeh Izadmehr, Menggang Yu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 18, 2026
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
Matthew D Galsky, Sudeh Izadmehr, Menggang Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2022
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma
Matthew Bootsma, Rana R McKay, Hamid Emamekhoo, et al.
JAMA Oncology
|
May 12, 2017
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
Shuang G Zhao, S Laura Chang, Nicholas Erho, et al.
The Lancet. Oncology
|
October 27, 2012
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
Kent A Robertson, Grzegorz Nalepa, Feng-Chun Yang, et al.
Journal of Clinical Medicine
|
October 26, 2024
From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
Bridget E Crossman, Regan L Harmon, Kourtney L Kostecki, et al.
Nature Medicine
|
January 19, 2024
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, et al.
Nature Medicine
|
October 2, 2023
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, et al.
The Journal of Clinical Investigation
|
November 1, 2022
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer
Shuang G Zhao, Jamie M Sperger, Jennifer L Schehr, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 176) with videos related to
Sort By:
Page
of 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2026
Gemcitabine plus nivolumab with carboplatin or oxaliplatin in cisplatin-ineligible patients with metastatic urothelial carcinoma: a randomized phase II trial
Ziao Li, Sudeh Izadmehr, Jeannie Hoffman-Censits, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 6, 2026
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
Matthew D Galsky, Sudeh Izadmehr, Menggang Yu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 18, 2026
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer
Matthew D Galsky, Sudeh Izadmehr, Menggang Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 26, 2022
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma
Matthew Bootsma, Rana R McKay, Hamid Emamekhoo, et al.
JAMA Oncology
|
May 12, 2017
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
Shuang G Zhao, S Laura Chang, Nicholas Erho, et al.
The Lancet. Oncology
|
October 27, 2012
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
Kent A Robertson, Grzegorz Nalepa, Feng-Chun Yang, et al.
Journal of Clinical Medicine
|
October 26, 2024
From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
Bridget E Crossman, Regan L Harmon, Kourtney L Kostecki, et al.
Nature Medicine
|
January 19, 2024
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, et al.
Nature Medicine
|
October 2, 2023
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, et al.
The Journal of Clinical Investigation
|
November 1, 2022
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer
Shuang G Zhao, Jamie M Sperger, Jennifer L Schehr, et al.
Page
of 18